Companies/Aequus Pharmaceuticals Inc.

Company profile

Aequus Pharmaceuticals Inc.

OTC: AQSZF · Healthcare · Drug Manufacturers - Specialty & Generic

Canadian filerHQ Vancouver, BCReports USD

#936 of 1,394 Healthcare companies by revenuetop-quartile growth

EA Score

——

FH —DQ —GM —SS 36

v0.1 · 5/100 weight · pillars only

↑ revenue growth (YoY), disclosure history · ↓ Altman-Z, balance-sheet leverage

Methodology →

Revenue TTM

$657.0k

Rev growth YoY (TTM)

+116.8%

Net income (FY)

-$1.6M

Employees

Market cap

$344.9k

Financials — latest annual

SEC EDGAR · USD-normalized

ConceptUSDNativeFY

Revenue$426.5k584.2k CAD2024

Net income-$1.6M-2.2M CAD2024

Operating income-$1.6M-2.1M CAD2024

Total assets$556.2k800.3k CAD2024

Liabilities$5.0M7.3M CAD2024

Equity-$4.5M-6.5M CAD2024

Revenue trend

FY2017 – FY2024 · USD

$877.4k

FY17

$1.1M

FY18

$1.2M

FY19

$1.9M

FY20

$2.2M

FY21

$1.1M

FY22

$188.9k

FY23

$426.5k

FY24

Revenue by segment

No segmentation disclosed for this filer. n/a

The read

Aequus Pharmaceuticals Inc. booked $426.5k in FY2024 revenue, growing 126% year over year — faster than most Healthcare companies we track, at a -372.7% net margin.

Peers · Healthcare

Resilient Healthcare Corp——EGF Theramed Health Corp.——Wesana Health Holdings Inc.——Inotiv, Inc.63C

Key facts

CEODouglas Glen Janzen

SectorHealthcare

IndustryDrug Manufacturers - Specialty & Generic

HeadquartersVancouver, BC

ExchangeOTC: AQSZF

Employees12

IPO date2015-06-16

Latest filings

No filings loaded — no CIK (non-SEC filer).

Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.